|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
gptkb:imdevimab
|
|
gptkbp:approvedBy
|
gptkb:FDA_(Emergency_Use_Authorization)
EMA (conditional)
|
|
gptkbp:ATCCode
|
J06BD39
|
|
gptkbp:CASNumber
|
2227361-79-9
|
|
gptkbp:combinationProduct
|
gptkb:REGEN-COV
|
|
gptkbp:developedBy
|
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:discoveredIn
|
2020
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
casirivimab
|
|
gptkbp:indication
|
mild to moderate COVID-19
post-exposure prophylaxis of COVID-19
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
gptkb:IgG1_kappa
|
|
gptkbp:mechanismOfAction
|
neutralizes SARS-CoV-2
|
|
gptkbp:monoclonalAntibodyType
|
fully human
|
|
gptkbp:notRecommendedFor
|
hospitalized COVID-19 patients requiring oxygen
|
|
gptkbp:routeOfAdministration
|
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
fever
nausea
rash
allergic reactions
infusion-related reactions
|
|
gptkbp:target
|
gptkb:SARS-CoV-2_spike_protein
|
|
gptkbp:UNII
|
4N6U6XOX4F
|
|
gptkbp:usedFor
|
gptkb:COVID-19
|
|
gptkbp:bfsParent
|
gptkb:REGEN-COV_(casirivimab_and_imdevimab)
gptkb:REGEN-COV
|
|
gptkbp:bfsLayer
|
7
|